Search clinical trials for: Janus Kinase Inhibitors

Total 64617 results

Alimentiv Inc.
Alimentiv Translational Research Consortium

Terminated

Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis (PROPHETIC)

Ulcerative Colitis

Netherlands
Lisa Barrett
Nova Scotia Health Authority; Dalhousie University

Active, not recruiting

Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients

COVID-19

Canada
Vanderson Geraldo Rocha

Terminated

Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19 (RUXO-COVID)

SARS-CoV2 | Severe Acute Respiratory Syndrome Coronavirus 2

Brazil
Leiden University Medical Center
Galapagos NV

Recruiting

JAK Inhibition in Ulcerative Colitis

Colitis, Ulcerative

Netherlands
Zhejiang Provincial People's Hospital

Recruiting

Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

Rheumatoid Arthritis | Treatment Compliance | Abatacept

China
Incyte Corporation

Terminated

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

COVID-19

United States, Russian Federation
Pfizer

Recruiting

Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis (TOFAST)

Ulcerative Colitis

France
Bangabandhu Sheikh Mujib Medical University, Dhaka...
Incepta Pharmaceuticals Ltd

Completed

Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study

Axial Spondyloarthritis

Bangladesh
Shanghai East Hospital

Active, not recruiting

A Study to Evaluate JAK Inhibitor Cream in EGFR-inhibitor-induced Skin Rash

Acneiform Eruptions

China
Pfizer

Recruiting

Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden (ODEN)

Ulcerative Colitis

Sweden
Institute of Biomedical Chemistry, Russia
Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy

Completed

Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs and Janus (JAK) Kinase Inhibitors

Rheumatoid Arthritis

Russian Federation
Sohag University

Recruiting

Polymorphism of Janus Kinase 1 and 2 (JAK 1&2) in Patients With Alopecia Areata

Alopecia Areata

Egypt
Pfizer

Recruiting

Korean Post-marketing Surveillance for Xeljanz XR (XRPMS)

Active Psoriatic Arthritis | Active Ankylosing Spondylitis | Active Moderate to Severe Rheumatoid Arthritis

Korea, Republic of
University Hospital, Lille
Pfizer

Terminated

Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the TOFAT Project (TOFAT)

Rheumatoid Arthritis

France
CTI BioPharma

Terminated

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

COVID-19 | COVID | COVID19

United States
John Reneau

Recruiting

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

T-Cell Large Granular Lymphocyte Leukemia

United States
Jinnah Hospital

Completed

Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.

Alopecia Areata | Alopecia Totalis | Alopecia Universalis

Pakistan
Pfizer

Completed

Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis (ESCALATE-RA)

Arthritis, Rheumatoid

Germany
Pfizer

Completed

Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.

Arthritis Rheumatoid

United States
Children's Hospital Medical Center, Cincinnati
Pfizer

Completed

Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus

Systemic Lupus Erythematosus | Cutaneous Lupus

United States
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients

Dermatomyositis, Adult Type

China
Liga Panamericana de Asociaciones de Reumatologia...

Recruiting

PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors (PREJAK)

Arthritis, Rheumatoid | Arthritis, Psoriatic | Spondyloarthritis

Argentina
Pfizer

Recruiting

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Israel, Poland, Canada, Japan, Belgium, Spain, Hungary, Finland, France, United Kingdom, Australia, Germany, Italy, Sweden, Netherlands, Slovakia
Pfizer

Completed

IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis

Arthritis, Rheumatoid

France
Pfizer

Completed

Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis

Psoriatic Arthritis

China
Shanghai Zhongshan Hospital

Not yet recruiting

The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis

Glucocorticoid Resistant ICIs-related Myocarditis
Yanfeng Hou

Recruiting

Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis

Rheumatoid Arthritis | Therapy

China
William Shomali
Incyte Corporation

Recruiting

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Eosinophilia | Hypereosinophilic Syndrome | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Splenomegaly | Hepatomegaly | Chronic Eosinophilic Leukemia, Not Otherwise Specified | JAK2 Gene Mutation | BCR-JAK2 Fusion Protein Expression | Blasts 20 Percent or Less of Peripheral Blood White... and other conditions

United States
University of Texas Southwestern Medical Center
Pfizer

Recruiting

Tofacitinib in Recurrent GBM Patients

Glioblastoma

United States
AbbVie

Active, not recruiting

A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis (Flex-Up)

Atopic Dermatitis

Australia, Belgium, Bulgaria, Canada, China, Germany, Hungary, Italy, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Slovakia, Spain, Taiwan, United Kingdom, Japan
AbbVie

Completed

A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

Hidradenitis Suppurativa (HS)

United States, Canada, Japan, Puerto Rico
Instituto de Investigación Sanitaria de la Fundación...
Hospital Universitario de Móstoles

Not yet recruiting

Response to Upadacitinib of Enthesitis Evaluated by Ultrasound in Patients With Psoriatic Arthritis

Psoriatic Arthritis

Spain
Charite University, Berlin, Germany
Pfizer

Not yet recruiting

ToFAcitinib in Early Active Axial SpondyloarThritis: (FASTLANE)

Axial Spondyloarthritis
AbbVie

Recruiting

A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting (UpSPINE)

Axial Spondylarthritis (r-axSpA)

Germany
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis

Prurigo Nodularis | Itch

China
National Institute of Allergy and Infectious Diseases...

Completed

Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus

Systemic Lupus Erythematosus | Cutaneous Lupus

United States
University of Colorado, Denver
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Recruiting

Tofacitinib for Immune Skin Conditions in Down Syndrome

Psoriasis | Down Syndrome | Vitiligo | Hidradenitis Suppurativa | Alopecia Areata | Atopic Dermatitis / Eczema

United States
Cedars-Sinai Medical Center

Terminated

Tofacitinib For Treatment Of Chronic Pouchitis

Pouchitis | Ileal Pouch | Ileal Pouchitis

United States
AbbVie

Completed

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy

Crohn's Disease
Khashayar Esfahani

Recruiting

Tofacitinib for the Treatment of Refractory Immune-related Colitis From Checkpoint Inhibitor Therapy- TRICK Study

Immune-Mediated Colitis

Canada
Institute of Dermatology, Thailand

Enrolling by invitation

Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study (Tofacitinib)

Frontal Fibrosing Alopecia | Lichen Planopilaris

Thailand
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

Hematopoietic and Lymphoid Cell Neoplasm | Steroid Refractory Graft Versus Host Disease

United States
AbbVie

Recruiting

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)

Systemic Lupus Erythematosus

United States, Japan, Puerto Rico, Switzerland, Israel, Korea, Republic of, Hungary, New Zealand, Bulgaria, Latvia, Taiwan, Slovakia, Croatia, South Africa, Australia, Poland, Portugal, Spain, Estonia, France, Lithuania, Brazil, Ger... and more
AbbVie

Active, not recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up)

Atopic Dermatitis

United States, Australia, Belgium, Bulgaria, Canada, China, Denmark, France, Germany, Hungary, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Romania, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwa... and more
Pfizer

Active, not recruiting

Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis (KRXeljanzJIA)

Polyarticular Juvenile Idiopathic Arthritis | Psoriatic Arthritis, Juvenile

Korea, Republic of
Sixth Affiliated Hospital, Sun Yat-sen University

Completed

Efficacy and Safety Analysis of Upadacitinib in Inflammatory Bowel Disease

Inflammatory Bowel Diseases

China
AbbVie

No longer available

Expanded Access to Upadacitinib

Atopic Dermatitis (AD)
AbbVie

Not yet recruiting

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

Crohn's Disease
AbbVie

Recruiting

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

Ulcerative Colitis

United States, Japan, Spain, Korea, Republic of, Taiwan, Bulgaria, Italy, Poland, France, United Kingdom, Greece, New Zealand, Australia, Belgium, Israel, Hungary, Netherlands
AbbVie

Active, not recruiting

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

Crohn's Disease (CD)

United States, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Romania, Slovakia, Spain, United Kingdom

Search clinical trials for: Janus Kinase Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations